title: Low serum adiponectin level as a predictor of impaired glucose regulation and type 2 diabetes mellitus in a middle-aged Finnish population.
abstract: Low levels of adiponectin are associated with obesity and type 2 diabetes mellitus (DM2). However, only few studies on this topic have used the most recent World Health Organization 1999 criteria, which include a definition of impaired glucose regulation (IGR). Our objective was to find out if a baseline low adiponectin level in initially normoglycemic subjects predicted IGR or DM2 during a mean follow-up period of 5.1 years. A population-based cohort study was carried out in Oulu, Northern Finland. Subjects born in 1935 and living in Oulu in 1990 were invited to participate in a follow-up study. At baseline, oral glucose tolerance tests and measurements of adiponectin, lipids, blood pressure, and body mass index were performed; and oral glucose tolerance tests were repeated at follow-up. Analyses were performed for 201 subjects who were normoglycemic at baseline. Low adiponectin level was defined as the lowest quartile of adiponectin levels. During the follow-up, 47 (23%) of the 201 subjects developed IGR or DM2. Impaired glucose regulation or DM2 developed in 15 of 41 (37%) subjects with low adiponectin level at baseline, whereas the corresponding proportion was 32 of 160 (20%) subjects with higher adiponectin levels (P = .025). In logistic regression analysis, the adjusted odds ratio for IGR or DM2 was 2.1 (95% confidence interval, 1.0-4.5) when adjustment was made for sex and body mass index. Low concentrations of adiponectin predicted subsequent development of IGR and DM2 in initially normoglycemic middle-aged Finnish subjects. Our findings support the hypothesis that adiponectin may play a role in the pathogenesis of abnormal glucose metabolism.
authors.affiliation: Institute of Health Sciences, University of Oulu, Box 5000, FIN-90014 Oulu, Finland. kirsti.jalovaara@oulu.fi
authors.forename: Kirsti
authors.initials: K
authors.lastname: Jalovaara
authors.forename: Merja
authors.initials: M
authors.lastname: Santaniemi
authors.forename: Markku
authors.initials: M
authors.lastname: Timonen
authors.forename: Jari
authors.initials: J
authors.lastname: Jokelainen
authors.forename: Y Antero
authors.initials: YA
authors.lastname: Kesäniemi
authors.forename: Olavi
authors.initials: O
authors.lastname: Ukkola
authors.forename: Sirkka
authors.initials: S
authors.lastname: Keinänen-Kiukaanniemi
authors.forename: Ulla
authors.initials: U
authors.lastname: Rajala
mesh_terms: D052242:Adiponectin / Q000097:blood; D001794:Blood Pressure / Q000502:physiology; D015992:Body Mass Index; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D015331:Cohort Studies; D003924:Diabetes Mellitus, Type 2 / Q000097:blood*; D005260:Female; D005387:Finland; D005500:Follow-Up Studies; D005947:Glucose / Q000378:metabolism*; D006801:Humans; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D014280:Triglycerides / Q000097:blood
chemical_list: C499918:ADIPOQ protein, human; D052242:Adiponectin; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D014280:Triglycerides; D005947:Glucose